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412Objectives: The incidence and consequence of an isolated involved circumferential radial margin (CRM) after
resection for esophageal adenocarcinoma in the setting of neoadjuvant chemoradiotherapy (CRT) has not been
reported. We aimed to determine the frequency and significance of a close (<1 mm) or involved CRM in patients
undergoing esophagectomy after CRT.
Methods:We retrospectively analyzed the data from patients undergoing resection from 1997 to 2008 for esoph-
ageal adenocarcinoma after neoadjuvant CRT. A positive CRMwas defined as microscopic tumor at or less than
1 mm of the radial margin. An R1 resection was tumor at the radial margin. Only patients with ypT3 or greater
tumors were included. R2 resections were excluded. Statistical comparisons were performed using Cox regres-
sion and Kaplan-Meier analyses.
Results: A total of 160 patients met the inclusion criteria, 42 (26%) had a positive CRM. The median survival
did not significantly differ between the CRM-negative and -positive groups (28 vs 50 months, P ¼ .84). A pro-
pensity score matching analysis also failed to find a significant difference in outcomes. When analyzed by tumor
present at the margin (R1), R0 patients had a longer median survival compared with R1 patients (28 vs 8 months,
P ¼ .01). This difference, however, was not seen on propensity score matching.
Conclusions:Resections of locally advanced esophageal adenocarcinomawith residual transmural viable tumor
after CRT frequently showed involvement of the radial margin with tumor either close to or at the margin. Tumor
close (<1 mm) to the radial margin did not result in a significant decrease in overall or disease-free survival or
increase in local recurrence. (J Thorac Cardiovasc Surg 2012;143:412-20)The significance of circumferential radial margin (CRM)
status in esophageal cancer first gained attention after it
was found that a positive CRM in rectal cancer purported
greater local recurrence rates. Controversy exists regarding
the significance of a close (<1 mm) or microscopically pos-
itive CRM after esophagectomy for esophageal cancer.
Most studies have shown that a close or involved CRM is
associated with shorter overall survival in patients who
have undergone surgery alone or neoadjuvant chemother-
apy.1-5 However, studies of the incidence and significance
of a positive CRM in patients with adenocarcinomae Department of Thoracic and Cardiovascular Surgery, University of Texas
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radiotherapy (CRT) are lacking.
Currently, there are two definitions of a positive esopha-
geal CRM. First, the College of American Pathologists
(CAP) has defined a positive CRM as tumor at the cut mar-
gin of resection. Alternatively, the Royal College of Pathol-
ogists (RCP) consider tumor at or within 1 mm of the
margin to be positive. Of particular relevance, most pub-
lished, peer-reviewed studies aiming to define the effect
of a positive CRM have used the RCP definition.
CRT before esophagectomy has been shown to improve
local control and survival compared with surgery alone.6-8
CRT has been shown to induce a complete oncologic
response in approximately 25% to 35% of patients with
esophageal cancer and to significantly improve the R0
resection rate.9,10 Currently, trimodality therapy (ie,
neoadjuvant CRT followed by surgery) has been
increasingly used in the treatment of esophageal cancer.
The purpose of the present study was to determine the
frequency and outcome of a positive CRM in patients un-
dergoing esophagectomy after CRT in an off-protocol set-
ting. To analyze patients with a similar risk of a positive
CRM, we focused our study on patients who were foundery c February 2012
Abbreviations and Acronyms
CAP ¼ College of American Pathologists
CI ¼ confidence interval
CRM ¼ circumferential radial margin
CRT ¼ concurrent radiotherapy
HR ¼ hazard ratio
RCP ¼ Royal College of Pathologists
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SMATERIALS AND METHODS
Patients were selected from a comprehensive, prospective database
that includes all patients undergoing surgical resection for esophageal
cancer at the University of Texas M.D. Anderson Cancer Center. Data
are entered during the preoperative evaluation, at the time of operation,
on the day of discharge, and at every postoperative outpatient encounter.
The present study was a retrospective review of that database and has
been approved by the University of Texas M.D. Anderson Cancer Center
institutional review board; the requirement of individual consent was
waived.
All patients who underwent esophagectomy at the University of Texas
M.D. Anderson Cancer Center from January 1, 1997 to December 31,
2008 and who received neoadjuvant chemoradiotherapy for middle to dis-
tal esophageal adenocarcinoma and gastroesophageal junction type I and II
were included. The patients who underwent emergent operations, reopera-
tions, or R2 resections or who died during the perioperative hospitalization
were excluded. Patients with unknown nodal status or systemic metastases
were also excluded. Thus, our cohort included only patients with ypT3 or
greater tumors.
Because we sought to evaluate the effect of an isolated, positive CRM,
the patients with positive proximal and distal margins were also excluded.
Therefore, the CRM-negative group contained patients with no positive
margins and the CRM-positive group has isolated, positive radial margins.
For the purposes of the present study, a positive CRM was defined in
agreement with the RCP definition (ie, tumor at or within 1mmof the radial
margin). However, for clarity of data collection and differentiation, we de-
fined an R1 resection as tumor at the radial margin, similar to the CAP
criteria.
The demographic, patient, and tumor characteristics were recorded.
These included age; body mass index; gender; race; number of positive
lymph nodes; American Joint Committee on Cancer, 6th edition, clinical
stage; American Joint Committee on Cancer, 7th edition, pathologic stage;
American Society of Anesthesiologists risk score; peripheral vascular dis-
ease; coronary artery disease; diabetes; renal insufficiency; alcohol abuse
(4 oz/d or equivalent); tobacco use; congestive heart failure; chronic ob-
structive pulmonary disease (requiring chronic bronchodilator use); weight
loss; grade (differentiation) of adenocarcinoma; and proximal, distal, and
radial margin status.
These variables were summarized with the use of descriptive character-
istics and compared with the use of t tests and chi-square analyses. Cox re-
gression analysis with stepwise backward elimination was used for
univariate andmultivariate analyses. First, univariate analysis of all charac-
teristics was performed. The variables with P<.25 on univariate analysis
were then entered into a multivariate logistic regression model. Signifi-
cance in the multivariate analysis was defined as P< .05. Propensity
matched analyses were performed for both ypT3 CRM-positive and R1
subgroups.The Journal of Thoracic and CaThe primary outcome was survival, defined as the interval from surgery
to death. The secondary outcomes include local recurrence and disease-free
survival. These outcomes were analyzed using Kaplan-Meier analysis and
the log-rank test.RESULTS
Incidence in the Cohort
A total of 160 patients during the study period met our
previously stated inclusion criteria and had a pathologic
classification of ypT3 or greater (ypT3þ). Of these 160 pa-
tients, 42 (26%) had an isolated, positive CRM. Also, 8 pa-
tients with ypT3þ (5%) underwent R1 resection solely
because of tumor at the radial margin (ie, proximal and dis-
tal margins were negative). The demographic, patient, and
tumor characteristics of the CRM-negative and -positive
groups were comparable and are listed in Table 1.Survival by RCP Criteria
A positive CRM was not significant on univariate analy-
sis for survival (hazard ratio [HR], 0.95; 95% confidence
interval [CI], 0.56–1.60). On multivariate analysis, the
number of positive lymph nodes (HR, 1.10; 95% CI,
1.04–1.17) and clinical stage IV (HR, 2.86; 95% CI,
1.30–6.26) emerged as independent predictors of survival
(Table 2).
The median and 5-year survival for the ypT3þ
CRM-negative (28 months and 25%, respectively) and
CRM-positive (50 months and 43%, respectively) also
did not differ significantly (P ¼ .84; Figure 1).Local Recurrence Using RCP Criteria
Of the 160 patients, 11 (7%) developed local recurrence,
defined as tumor occurring within the esophageal or gastric
remnant. Of the 11 local recurrences, 7 (4%; range, 5–39
months) were CRM negative and 4 (2%; range, 6–32
months) were CRM positive. The incidence of local recur-
rencewas not significantly different between the two groups
(P ¼ .16; Figure 1).
A positive CRM was not significant on univariate analy-
sis for local recurrence (HR, 2.36; 95% CI, 0.69–8.11).
Multivariate analysis revealed that the number of positive
lymph nodes (HR, 1.43; 95% CI, 1.19–1.72), tumor loca-
tion (HR, 0.01; 95% CI, 0.00–0.6), and alcohol abuse
(HR, 5.15; 95% CI, 1.36–19.47) were independent predic-
tors of local recurrence (Table 2).Disease-Free Survival Using RCP Criteria
A CRM was also not significant (HR, 0.78; 95% CI,
0.48–1.27) on univariate analysis for disease-free survival.
Multivariate analysis revealed that the ypN descriptor
(ypN2, HR, 1.82; 95% CI, 1.05–3.13; ypN3, HR, 3.46;
95% CI, 1.71–6.98) was an independent predictor of
disease-free survival (Table 2).rdiovascular Surgery c Volume 143, Number 2 413
TABLE 1. Demographic, patient and tumor characteristics of cohort
by CRM status using RCP criteria
Variable
Negative
CRM
Positive
CRM
P
value
Patients (n) 118 42
Age* (y) .98
Mean 60 61
Range 23–80 37–84
Positive lymph nodes (n) .11
Median*,y 0 1
Range 0–20 0–14
Gender 1.00
Male 108 (92) 39 (92)
Female 10 (8) 3 (8)
Race .20
White 110 (93) 36 (86)
Other 8 (7) 6 (14)
ASA score 1.00
1–2 27 (23) 10 (24)
3–4 91 (77) 32 (76)
Preoperative radiation dose (cGy) .02
45 47 (40) 8 (19)
>45 71 (60) 34 (81)
Surgery type .25
Ivor Lewis 84 (71) 25 (60)
Transhiatal 16 (14) 6 (14)
Three-field 12 (10) 5 (12)
Minimally invasive 6 (5) 6 (14)
Resection extent*,z .00
R0 118 (100) 34 (81)
R1 0 (0) 8 (19)
Pathologic N statusz .37
N0 62 (52) 16 (38)
N1 32 (27) 15 (36)
N2 15 (13) 8 (19)
N3 9 (8) 3 (7)
Pathologic stage (AJCC 7th edition) .37
IIB 62 (53) 16 (38)
IIIA 32 (27) 15 (36)
IIIB 15 (13) 8 (19)
IIIC 9 (8) 3 (7)
Grade (differentiation) .84
Well/moderately 32 (28) 10 (25)
Poorly/undifferentiated 82 (72) 30 (75)
Tumor locationy 1.00
Middle 4 (3) 1 (2)
Lower/GEJ 114 (97) 41 (98)
Data presented as numbers, with percentages in parentheses. CRM, Circumferential
radial margin; ASA, American Society of Anesthesiologists; AJCC, American Joint
Committee on Cancer; GEJ, gastroesophageal junction. *Carried into multivariate
analysis for survival outcome; also included in multivariate analysis, but not above:
clinical stage. yCarried into multivariate analysis for local recurrence outcome;
also included in multivariate analysis, but not above: alcohol abuse. zCarried into
multivariate analysis for disease-free survival outcome.
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CRM-negative group (16 months and 25%, respectively)
and CRM-positive group (18 months and 41%, respec-
tively) did not differ significantly (P ¼ .31; Figure 1).414 The Journal of Thoracic and Cardiovascular SurgPropensity Score Match Using RCP Criteria
A propensity score match for the patients with ypT3þwas
also performed. Forty-four pairs of the ypT3þ subgroup
were matched by age, number of lymph nodes checked,
number of positive lymph nodes, body mass index, gender,
race, tumor location, type of esophageal surgery, clinical
stage, American Society of Anesthesiologists score, periph-
eral vascular disease, coronary artery disease, alcohol
abuse, congestive heart failure, chronic obstructive pulmo-
nary disease, recent weight loss, diabetes, tobacco use, and
pathologic N status. No statistically significant difference
was found in survival (P ¼ .97), local recurrence
(P ¼ .23), or disease-free survival (P ¼ .52) between pa-
tients with or without an involved CRM using the RCP
criteria.Survival Using CAP Criteria
The median and 5-year survival for the R0 patients was
significantly longer than the R1 patients (28 versus 8
months and 28% vs 19%, respectively; P ¼ .01; Figure 2).Local Recurrence Using CAP Criteria
Of the 11 local recurrences, 10 (6%) were in the R0
group and 1 (1%) in the R1 group. No statistically signifi-
cant difference was found in local recurrence between the
two groups (P ¼ .17; Figure 2).Disease-Free Survival Using CAP Criteria
The median and 5-year disease-free survival for the R0
group was also significantly longer than that of the R1 group
(18 vs 8 months and 29% vs 0%, respectively; P ¼ .02;
Figure 2).Propensity Score Match Using CAP Criteria
Again, we performed a propensity score match, but this
time compared the outcomes using the CAP criteria for
a positive radial margin. Eight pairs were matched by age,
number of lymph nodes checked, number of positive lymph
nodes, body mass index, gender, race, tumor location, type
of esophageal surgery, clinical stage, American Society of
Anesthesiologists score, peripheral vascular disease, coro-
nary artery disease, alcohol abuse, congestive heart failure,
recent weight loss, diabetes, tobacco use, radiation dose,
and pathologic N status. No statistically significant differ-
ence was found in survival (P ¼ .97), local recurrence
(P ¼ .38), or disease-free survival (P ¼ .14) between pa-
tients with an involved CRM using the CAP criteria
(Figure 2).Multivariate Analysis for Outcomes: Involved CRM
and R1 Resection
Finally, we performed univariate and multivariate analy-
ses for independent predictors of close (CRM positive) andery c February 2012
TABLE 2. Results of univariate and multivariate analysis of cohort for outcomes: overall and disease-free survival and local recurrence
Factors significant on univariate analysis
Overall survival Disease-free survival Local recurrence
Variable HR (95% CI) Variable HR (95% CI) Variable HR (95% CI)
Age 1.02 (1.00–1.04) Age 1.01 (1.00–1.03) CHF 36.09 (3.19–407.87)
Positive lymph nodes 1.11 (1.05–1.18) Positive lymph nodes 1.10 (1.05–1.16) Positive lymph nodes 1.29 (1.11–1.49)
BMI 25 kg/m2 0.77 (0.51–1.19) ASA score 3–4 1.62 (0.96–2.73) BMI 25 kg/m2 0.27 (0.08–0.92)
Female gender 0.60 (0.26–1.38) Clinical stage III 1.45 (0.92–2.28) White race 0.29 (0.08–1.08)
Clinical stage IV 2.00 (0.96–4.19)
Lower tumor location 0.43 (0.16–1.18) ypN2 1.81 (1.05–3.11) Lower tumor location 0.02 (0.00–0.11)
ypN3 3.56 (1.95–7.64)
Clinical stage III 1.45 (0.89–2.36) Weight loss in past 3 mo 1.27 (0.86–1.89) Alcohol use 4 oz/d 3.88 (1.18–12.75)
Clinical stage IV 2.36 (1.10–5.11)
ASA 3-4 1.85 (1.03–3.33) Diabetes 1.35 (0.83–2.21) CRM Positive 2.36 (0.69–8.11)
CHF 2.71 (0.85–8.67) R1 resection 2.48 (1.14–5.39) R1 resection 3.84 (0.48–30.98)
Weight loss in past 3 mo 1.33 (0.88–2.02) ypN2 5.69 (1.23–26.40)
ypN3 11.95 (1.86–76.86)
R1 resection 2.91 (1.26–6.74)
ypN2 2.03 (1.14–2.57)
ypN3 3.19 (1.57–6.47)
Factors significant on multivariate analysis
Positive lymph nodes 1.10 (1.04–1.17), P ¼ .00 ypN2 1.82 (1.05–3.13), P ¼ .03 Positive lymph nodes 1.43 (1.19–1.72), P ¼ .00
ypN3 3.46 (1.71–6.98), P ¼ .00
Clinical stage IV 2.86 (1.30–6.26), P<.01 Lower tumor location 0.01 (0.00–0.06), P ¼ .00
Alcohol use 4 oz/d 5.15 (1.36–19.47), P ¼ .02
Variables included in univariate analysis are listed in the ‘‘Materials and Methods’’ section. Variables with P<.25 on univariate analysis were included multivariate analysis.
HR, Hazard ratio; CI, confidence interval; CHF, congestive heart failure; BMI, body mass index; ASA, American Society of Anesthesiologists.
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cluded in the univariate and multivariate analyses for sur-
vival, local recurrence, and disease-free survival were
included in this analysis.
The patient variables found to be significantly predictive
of a positive CRM included a history of congestive heart
failure (odds ratio [OR], 12.39; 95% CI, 1.19–128.95)
and a history of tobacco use (OR, 0.44; 95%CI, 0.21–0.95).
The independent predictors of an R1 resection included
the numbers of lymph nodes checked (OR, 0.87; 95% CI,
0.77–0.98); presence of peripheral vascular disease (OR,
26.17; 95%CI, 1.26–544.20); and American Joint Commit-
tee on Cancer, 7th edition, pathologic stage III (OR, 26.90;
95% CI, 1.59–454.89).
DISCUSSION
In summary, no difference in survival, local recurrence,
or disease-free survival was seen when defining a radial
margin using the RCP criteria. When using the CAP defini-
tion for a positive radial margin, the cohort appeared to have
a significantly lower overall and disease-free survival. This
difference, however, was not seen on a propensity score
match analysis.
Our results have shown that in a group of patients with
adenocarcinoma of the esophagus who undergo resection
after neoadjuvant chemoradiotherapy, the incidenceThe Journal of Thoracic and Ca(26%) of a surgically positive CRM as defined by the
RCP is a frequent event. In this same group of patients,
a positive radial margin using the CAP definition is an infre-
quent event (5%).
There are several potential reasons for this to occur. The
addition of neoadjuvant chemoradiotherapy is known to im-
prove the chances of an R0 resection.11 We believe that for
patients with locally advanced disease, the addition of neo-
adjuvant multimodality therapy facilitates the course of the
operation, allowing the surgeon to more easily attain a com-
plete resection after a size reduction of the tumor brought
about by the additional local therapy. However, not all pa-
tients respond equally to therapy. Although all the patients
in the ypT3þsubgroup had residual viable tumor, those with
tumor at the margin might represent patients with more ad-
vanced disease or whose tumors were more resistant to neo-
adjuvant treatment.
Theoretically, the type of surgical resection can affect the
radial margin outcome, although in our study population,
we found no correlation between the resection type and
a positive radial margin. It is our policy to widely resect
at the area at which the tumor is at risk of radial invasion.
This includes resection of structures such as the pleura, di-
aphragm, pericardium, periaortic fat, and so forth. Exami-
nation of our data would note the infrequent use of
procedures that do not involve intrathoracic dissection.rdiovascular Surgery c Volume 143, Number 2 415
FIGURE 1. Kaplan-Meier curves for outcomes of cohort according to
Royal College of Pathologists (RCP) criteria.
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even after chemoradiotherapy and surgery, we have worried
about the utility of less-aggressive resection.8 Finally, full-
thickness lesions of the esophagus can involve structures
surrounded by a potential space, such as the pleura or peri-
toneal cavity. In these cases, the surgeon has no control over
the final radial margin evaluation.
Although the occurrence of a positive CRM using the
RCP criteria in our study was fairly frequent, the rate com-
pares favorably with that from other studies by Dexter and
colleagues,3 Sagar and colleagues,4 Scheepers and col-
leagues,2 Saha and colleagues,1 and Sujendran and col-
leagues.5 In these studies, the patients either received no
neoadjuvant therapy or neoadjuvant chemotherapy, or, in
the case of one study, neoadjuvant chemoradiotherapy
was given to a small minority of the total study population.
Those investigators described positive CRM rates of 36%
to 55%, and all found that a positive CRM, using the
RCP criteria, to be an independent predictor of survival.
Our results are important for several reasons. First, these
results contradict the findings of multiple studies that re-
viewed a close or involved CRM (RCP criteria). Dexter
and colleagues,3 Sagar and colleagues,4 Scheepers and col-
leagues,2 Saha and colleagues,1 and Sujendran and col-
leagues5 all found a close or positive CRM to be
independent predictors of survival and/or local recurrence.
Only Khan and colleagues12 failed to find this relationship.
Our results also contradict a recent study that indicatedCRM
using the RCP criteria is a significant factor associated with
survival in patients who received neoadjuvant chemoradio-
therapy for squamous cell carcinoma of the esophagus.13
Second, the more clinically relevant definition of a posi-
tive CRM might be tumor at the radial margin rather than
very close to it. Our data indicated that tumor close to the
margin is not a significant factor for survival, local recur-
rence, or disease-free survival. These results echo the find-
ings from Deeter and colleagues14 indicating that the CAP
definition of a positive CRM was more clinically meaning-
ful than the RCP definition.We believe that the lack of a sig-
nificant difference between outcomes in the propensity
score match analysis of the R1 and R0 groups resulted
from underpowering. Additional studies with a larger num-
ber of ypT3þR1 patients are needed to delineate the impor-
tance of tumor at the radial margin in patients undergoing
esophagectomy after CRT.
Finally, these data provide some clinically relevant infor-
mation. After surgery in which the surgeon believes a com-
plete resection has been have performed, the report of
a positive CRM as defined by the RCP criteria can easily
confuse both the patient and the clinician. According to
our results, the report of tumor close (within 1 mm) of the
radial margin in patients who received CRT does not por-
tend decreased overall and disease-free survival or a greater
incidence of local recurrence.ery c February 2012
FIGURE 2. Kaplan-Meier curves for outcomes of cohort according to College of American Pathologists (CAP) criteria by log-rank test and propensity
score match. LR, Log rank; PSM, propensity score matching.
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the CRM-positive and R1 radial margin groups (44 and 8
patients, respectively) were relatively small. This could
have led to underpowering, especially in the R1 group anal-
yses in which a type II error might have been present. Two,
the pathologic evaluation of the specimens is often per-
formed by a single pathologist without secondary verifica-
tion. Third, just as with any retrospective study, selection
bias is a concern. The propensity score match was per-
formed in an attempt to mitigate this sort of bias. Fourth,
it is difficult to establish a specific protocol for pathologic
fixation of specimens that simultaneously involve several
body cavities. Thus, there could be times when the surgeon
performs what they perceive to have been an R0 resection,
but a positive CRM is found because the envelope of sur-
rounding pleura or soft tissue was disrupted.CONCLUSIONS
A close (<1 mm) radial margin in patients undergoing
esophagectomy after neoadjuvant chemoradiotherapy
does not appear to be an independent predictor of survival,
local recurrence, or disease-free survival. An involved ra-
dial margin, however, might be the more clinically relevant
definition. Future studies concerning multimodality therapy
with chemoradiotherapy and surgery should include the
CAP definition of radial margin involvement.References
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DrGail E. Darling (Toronto, Ontario, Canada). I want to thank
Dr Harvin for an excellent presentation and for providing me with
the manuscript well in advance of the meeting.
You have addressed a very important question regarding posi-
tive circumferential radial margins, and, specifically, you have ad-
dressed the problem of two conflicting definitions. Your results
have shown that the Royal College of Pathologists’ definition
has no predictive value in terms of survival, and that is in contrast
to a number of other reports. How do you explain the difference in
your results compared with previous reports using that Royal Col-
lege definition?
Dr Harvin.Well, our data are unique in that all patients in this
analysis underwent neoadjuvant chemoradiotherapy. The other
studies that have looked at this subject have either contained
a very small percentage of patients receiving neoadjuvant chemo-
radiotherapy or none at all. We are in agreement with some other
studies. For example, Deeter, published a report in 2009 that
showed that the definition of a positive radial margin by the Col-
lege of American Pathology definition was a more clinically-rele-
vant definition. We certainly are in agreement with that study.
Compared with some of the other studies that our results contra-
dict, they only used the Royal College of Pathology definition.
They did not differentiate their patients by tumor at the margin ver-
sus tumor at or within. Because we don’t know the incidence or
significance of tumor at the margin in those studies, we could
not compare our results to theirs.
Dr Darling. Do you think that the radiation plays a significant
role in your ability to achieve an R0 resection?
Dr Harvin. There is level 1 data that R0 resections are more
common after neoadjuvant chemoradiotherapy rather than, say,
neoadjuvant chemotherapy or surgery alone. We believe that the
neoadjuvant chemoradiotherapy allows us to have more complete
resections. This was, however, not a randomized study, so we can-
not determine from this study what role radiation may play.
Dr Darling. My other question relates to your surgical ap-
proach. The majority of your patients had transthoracic resections.
Do you think that had an effect on your results?
Dr Harvin. In terms of the data, we did not see any difference
between the types of surgery and involved radial margins, so we
cannot say that the type of surgery affected our results. The num-
bers for some of the different types of operations were small, how-
ever, so it could have been underpowered.
Dr Darling. I’m sorry, I should have made my question more
clear. Do you think that that might explain the difference between
your results and some of the other studies?ery c February 2012
Harvin et al General Thoracic Surgery
G
T
SDr Harvin. I don’t think we can answer that question from the
data we have collected.
Dr Darling. You excluded patients with positive proximal or
distal resection margins, but it seems there’s only a very small
number of patients in that group. Do you think that if we exclude
patients with positive proximal and distal margins that it’s very
likely that the radial margin will also be negative? Can we use
that as a predictor?
Dr Harvin. Although it’s possible, the number of patients with
positive proximal or distal margins and a positive radial margin
were very few. So, I do not think we can use proximal or distal mar-
gin status as a marker for radial margin status.
Thank you, Dr. Darling, for your questions and for evaluating
the manuscript.
Dr BrendonM. Stiles (New York, NY). Thank you very much. I
enjoyed the talk.
I have two questions I was hoping to ask. One, can you predict
the type of patients who are going to have positive margins? Some
of that is by the type of surgery, but some also by the location of the
tumor, by the histology of the tumor.
Dr Harvin. Can you repeat your question?
Dr Stiles. Are you able to get a sense of which patients are go-
ing to have positive margins going in? Is there a predictor; the type
of surgery, whether they responded to induction therapy, the loca-
tion of the tumor, gastroesophageal junction versus lower
esophagus?
Dr Harvin.We do not have that analysis for the exact patients
we presented today. However, an older multivariate analysis of
similar ypT3 patients found that radiation doses greater than 45
Gy and pathologic lymph node status were independent predictors
of a positive CRM (tumor at or within 1mm of the radial margin).
Dr Stiles.My second question is how the patients responded to
induction therapy. I know that in a lot of the publications from your
institution, the response to neoadjuvant therapy has been a very
powerful predictor of outcome. We have seen similar results.
When we have tried to look at the effect of extended lymphadenec-
tomy in this kind of group of patients, what we have seen is that in
the responders it probably doesn’t matter as much because they
have a great systemic response and they are probably not going
to have as bad an outcome. Conversely, in the nonresponders,
we see that actually more aggressive local resection becomes
more important. Have you looked at the clinical response and
are you able to tell the difference between those two groups of
patients?
DrHofstetter. In a multivariate analysis, both histoviability and
response were included, and it wasn’t an independent predictor. So
we couldn’t predict whowas going to have a positive margin based
on whether they had a response or not, and that’s why, when we did
the original analysis, we included all patients and all comers rather
than focusing on just the ypT3s. The interesting finding in our data
was that when we looked at thewhole group, the CRM-positive pa-
tients actually performed slightly better than the CRM-negative
ones. If you recognize the first Kaplan-Meier curve, wewere above
it—and that was including all patients who were ypT0N0M0 as
well.
In terms of your question about location or histology, thosewere
both included and were not independent predictors, so we couldn’t
exactly delineate which were or which would not be. Now, I don’tThe Journal of Thoracic and Cawant to be the naysayer about the minimally invasive esophagec-
tomy (MIE) procedure, but I will say that perhaps early in our
learning curve, 50% of the patients who had undergone an MIE
procedure had a close margin, although, according to the CAP def-
inition, only 1 of 12 was positive. So this might, again, be early in
our learning curve. It was not statistically significant, but if there
was anything to delineate transthoracic versus transhiatal MIEs,
which at that point we were doing a lot of, we had a fewmore close
margins in that situation.
Dr Thomas W. Rice (Cleveland, Ohio). I have a comment
about your analysis. If you continue to distill your data, eventually
you’re going to select out the worst people, and if you perform
multiple, multiple tests, eventually one is going to be positive by
chance. I have some advice. This was a retrospective study. You
must match patients who don’t have a positive resection margin
with those who don’t have a positive resection margin, because
generally the people with the positive resection margins have the
bigger tumors. And you can’t compare a T1 to a T3. You have
to compare a T3 and a T3, a T3 with a positive resection margin
versus a T3 without. So you must propensity-match it and then
you can tell us. You’ll maximize the use of your data and you’ll
give us some very valuable information. Thank you very much.
Dr. Harvin.Actually, we did do a propensity score match and it
showed no difference. We did not include that because our patients
were so alike in the ypT3 group that we thought it wouldn’t add
much to the analysis.
Dr Rice. It’s much better to include it. It will make it a much
more valuable paper for the reviewers and the editors to see it.
Dr Harvin. Yes. Thank you, sir.
Dr Avi Lebenthal (Boston, Mass). I enjoyed your presentation.
The problem I have with this topic is the pathology; it’s not re-
ally the surgery. What we have learned from the analysis of nodes
in esophageal cancer is that when the Japanese cut them between 5
and 10 times, they get a very different incidence of node positivity
than we do when we cut them once or when in Belgium they cut
them 3 times. So it’s very different in different places. It could
be that the difference between the 1 mm and the positive margin
is a function of also how the pathologist is looking at it. So if
you really want to do this prospectively, I think, as a discipline,
we have to sort of decide what the pathologist has to analyze in
the tissue, because otherwise we’re all collecting different data.
Dr. Harvin. Yes, sir.
DrMark J. Krasna (Towson, Md). I enjoyed your presentation,
Dr. Harvin.
For you and Dr Hofstetter, there are data in rectal cancer that are
very similar to this that I’m sure you’re aware of if you looked at
circumferential radial margins because it’s the only other place we
look at it routinely. The reason I bring it up is, with the new staging
system,Wayne, you’re always talking about what’s the clinical ap-
plication, how are we going to use it in clinical hands. What they
do now in rectal cancer, based on the British data from multidisci-
plinary prospective reviews of MRIs, they predefine a subgroup of
patients who might be likely to have a circumferential radial mar-
gin versus those negative, and this answers what Brendon was get-
ting at. Do either of you have any thoughts about any of our current
diagnostic testing, whether it’s EUS or adding MRI in the esoph-
agus, like rectal, that you might be able to predetermine that group
of patients?rdiovascular Surgery c Volume 143, Number 2 419
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SDrHofstetter.That’s a good question,Mark, and thank you for it.
Our opinion in general, ongoing, is that we should be looking at
a positive circumferential radial margin as the most significant one
and that we need to be including that definition in our randomized
trials. Whether or not it’s at 1 mm or 2 mm, which is what the co-
lorectal surgeons have established, versus at the margin, I think
might be site specific and it might also be treatment-specific. So
we’re trying to establish that CAP is the most relevant criteria
and we’re going to advocate using that going forward. In terms
of what studies would be best for that, I don’t know. I think that
the pathologist makes a big difference, but also the surgery does
too. I know that most of you, after you have done your transtho-
racic or modified en bloc esophagectomy don’t go back and sew
the pleura down to where it was over the tumor, you know, to
say, well, don’t disrupt this when it goes on its way over to pathol-
ogy, and that might also have a significant effect on these close
margins. The positive margins are positive likely because the sur-
geon can’t go any further, meaning this is a T4a or it’s into the
pleura, and everything has been resected, and this is more of
a marker of disease than a marker of surgery.
Dr Krasna. Can EUS or MRI—?
Dr Hofstetter. I don’t know the answer to that. At our institu-
tion we had the guys doing EUS calling it T4a very frequently,
and we did not use that as an indicator to change our therapy or
change our operation, because not infrequently the call of T4420 The Journal of Thoracic and Cardiovascular Surgwas incorrect or it wasn’t borne out from the standpoint of surgery.
Now, whether that’s due to downstaging or not, I don’t have the
data for that.
Dr Scott Swanson (Boston, Mass). I really enjoyed that paper.
In follow-up to what you just said, what do you do with those pa-
tients who have tumor at the margin? If you’re giving them chemo-
radiotherapy, you know they are going to have a high chance of
local recurrence as well as systemic recurrence. What’s your treat-
ment modality? Is there a radiation strategy, pure chemo strategy,
IMRT? What do you do with them?
Dr Hofstetter. We entered into this project as a fact-finding
mission. We didn’t know quite what we were going to find with tu-
mor close to the margin versus at the margin. As you saw, it was
a fairly frequent finding for patients who were having a transmural
viable tumor but didn’t know whether it was at all significant.
I think it’s interesting to note that the patients who have disease
at the margin didn’t do as well, but their local recurrences weren’t
any higher, and I think it’s a marker for bad disease. Unfortunately,
as you know, at this point there are several indicators for patients
who are going to do poorly, none of which we know completely
how to treat, but excess lymph node involvement, lymphovascular
invasion, and I think disease at the margin is one of those other
poor indicators, but of systemic disease, not necessarily of locore-
gional failure. So maybe that’s something that we need to look at
into the future.ery c February 2012
